Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Stefan Sleijfer"'
Autor:
Patrick Schöffski, Ahmad Awada, Anne-Marie de la Bigne, Zakia Felloussi, Mike Burbridge, Frederique Cantero, Riccardo Colombo, Sara Maruzzelli, Katia Ammattatelli, Maja de Jonge, Philippe Aftimos, Herlinde Dumez, Stefan Sleijfer
Publikováno v:
European Journal of Cancer, 169, 135-145. Elsevier Ltd.
BACKGROUND: S81694 is an inhibitor of monopolar spindle 1 kinase, a target expressed in proliferating cells. CL1-81694-001 was the first-in-human study aiming at identifying a safe dosing schedule in solid tumour patients. PATIENTS AND METHODS: This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5105915d663ef0244a4dda06eebfbd04
https://lirias.kuleuven.be/handle/20.500.12942/697837
https://lirias.kuleuven.be/handle/20.500.12942/697837
Autor:
Milea J. M. Timbergen, Dirk J. Grünhagen, Cornelis Verhoef, Stefan Sleijfer, Anne-Rose W. Schut
Publikováno v:
European Journal of Cancer, 137, 18-29. Elsevier Ltd.
BACKGROUND: This study evaluates the results of the active surveillance (AS) approach in adult patients with desmoid-type fibromatosis (DTF) because AS is advocated as a front-line approach for DTF in the European consensus guidelines.METHODS: A syst
Autor:
Maurice P.H.M. Jansen, Paolo Vigneri, Stefan Sleijfer, Corine M. Beaufort, Silvia R. Vitale, John Martens, Anieta M. Sieuwerts, Anita M. A. C. Trapman-Jansen, A. Mieke Timmermans, Kirsten Ruigrok-Ritstier, Renée Foekens
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-16 (2022)
BMC Cancer, 22(1):165. BioMed Central Ltd.
BMC Cancer, 22(1):165. BioMed Central Ltd.
Background In breast cancer (BC), recurrent fusion genes of estrogen receptor alpha (ESR1) and AKAP12, ARMT1 and CCDC170 have been reported. In these gene fusions the ligand binding domain of ESR1 has been replaced by the transactivation domain of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e83b5eb241980e2a29bd5c0b52757a0
http://hdl.handle.net/20.500.11769/524144
http://hdl.handle.net/20.500.11769/524144
Autor:
Wouter Dercksen, Dinja T. Kruger, Agnes Jager, Inge R. H. M. Konings, John W.M. Martens, Maurice P.H.M. Jansen, Jamal Oulad Hadj, Stefan Sleijfer, Epie Boven
Publikováno v:
Molecular Oncology, Vol 14, Iss 3, Pp 490-503 (2020)
Molecular Oncology, 14, 490-503. John Wiley & Sons Ltd.
Kruger, D T, Jansen, M P H M, Konings, I R H M, Dercksen, W M, Jager, A, Oulad Hadj, J, Sleijfer, S, Martens, J W M & Boven, E 2020, ' High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2-postmenopausal breast cancer patients treated with everolimus and exemestane ', Molecular oncology, vol. 14, no. 3, pp. 490-503 . https://doi.org/10.1002/1878-0261.12617
Molecular Oncology
Molecular oncology, 14(3), 490-503. Elsevier
Molecular Oncology, 14, 490-503. John Wiley & Sons Ltd.
Kruger, D T, Jansen, M P H M, Konings, I R H M, Dercksen, W M, Jager, A, Oulad Hadj, J, Sleijfer, S, Martens, J W M & Boven, E 2020, ' High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2-postmenopausal breast cancer patients treated with everolimus and exemestane ', Molecular oncology, vol. 14, no. 3, pp. 490-503 . https://doi.org/10.1002/1878-0261.12617
Molecular Oncology
Molecular oncology, 14(3), 490-503. Elsevier
We determined whether progression-free survival (PFS) in metastatic breast cancer (MBC) patients receiving everolimus plus exemestane (EVE/EXE) varies depending on circulating tumour DNA (ctDNA) characteristics. Baseline plasma cell-free DNA (cfDNA)
Autor:
Hans Gelderblom, Henk-Jan Guchelaar, Jacqueline S. L. Kloth, Neeltje Steeghs, Stefan Sleijfer, Michiel C. Verboom, Ron H.J. Mathijssen, Anna K.L. Reyners, Jesse J. Swen
Publikováno v:
Pharmacogenomics Journal
Pharmacogenomics Journal, 19(5), 473-479. NATURE PUBLISHING GROUP
Pharmacogenomics journal, 19(5), 473-479. Nature Publishing Group
Pharmacogenomics Journal, 19(5), 473-479. Nature Publishing Group
Pharmacogenomics Journal, 19(5), 473-479. NATURE PUBLISHING GROUP
Pharmacogenomics journal, 19(5), 473-479. Nature Publishing Group
Pharmacogenomics Journal, 19(5), 473-479. Nature Publishing Group
Imatinib has a mild toxicity profile, although severe adverse events may develop. In this pharmacogenetic pathway analysis the need for dose reduction and cessation of therapy was tested for an association with single nucleotide polymorphisms (SNPs)
Autor:
K. de Joode, R van Rijn, Ellen Kapiteijn, A.J. ten Tije, Geke A. P. Hospers, Stefan Sleijfer, J.W.B. de Groot, Djura Piersma, Piotr Rutkowski, Karijn P M Suijkerbuijk, Bettina Ryll, J.B.A.G. Haanen, A.A.M. Van der Veldt, Maureen J.B. Aarts, Marye J Boers-Sonderen, Evalyn E. A. P. Mulder, G. Vreugdenhil, Saskia Litière, E. Oomen-de Hoop, F.W.P.J. van den Berkmortel, A.J.M. van den Eertwegh, M Franken
Publikováno v:
BMC Cancer, 21(1):323. BioMed Central Ltd
BMC Cancer, 21(1):323. BMC
BMC Cancer, 21
BMC Cancer, 21(1). BMC
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer, 21(1):323. BioMed Central Ltd.
BMC Cancer, 21, 1
BMC Cancer, 21(1):323. BMC
BMC Cancer, 21
BMC Cancer, 21(1). BMC
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer, 21(1):323. BioMed Central Ltd.
BMC Cancer, 21, 1
Background The introduction of programmed cell death protein 1 (PD-1) blockers (i.e. nivolumab and pembrolizumab) has significantly improved the prognosis of patients with advanced melanoma. However, the long treatment duration (i.e. two years or lon
Autor:
Stefan Sleijfer, Paul Hamberg, Marcel Smid, Mieke Timmermans, Wendy Onstenk, John W.M. Martens, Jaco Kraan, Agnes Jager, Felix E. de Jongh, Ingeborg E. de Kruijff, Anieta M. Sieuwerts
Publikováno v:
International Journal of Cancer, 145(4), 1083-1089. Wiley-Liss Inc.
The androgen receptor (AR) has potential clinical relevance in metastatic breast cancer (mBC) since it might be a treatment target and has been associated with endocrine resistance. A minimal-invasive way to determine AR expression on metastatic tumo
Publikováno v:
Oncologist, 24(7), E526-E535. AlphaMed Press
BACKGROUND. Treatment options for patients with metastatic soft tissue sarcoma (STS) have increased in the last decade. We aimed to examine whether this is associated with improved overall survival (OS) in patients with STS with synchronous metastase
Autor:
Stefan Sleijfer, A. Lecyk, Melissa Vos, Piotr Rutkowski, Dirk J. Grünhagen, Hanna Koseła-Paterczyk, Cees Verhoef, G J L H van Leenders, M. Normantowicz
Publikováno v:
European Journal of Surgical Oncology, 44(9), 1391-1397. W.B. Saunders
BACKGROUND: Liposarcomas can be divided into four subtypes and are most frequently located in the extremities. There are currently no studies comparing the clinical outcomes, such as local recurrence and distant metastasis, between the distinct subty
Autor:
Yarne Klaver, Dirk J. Grünhagen, Rebecca Wijers, Stefan Sleijfer, Astrid A. M. Oostvogels, Cornelis Verhoef, Maud Rijnders, Marcel Smid, Reno Debets, Cor H. J. Lamers
Publikováno v:
Journal for ImmunoTherapy of Cancer, 8(2):e000271. BioMed Central Ltd.
IntroductionLocal T-cell immunity is recognized for its contribution to the evolution and therapy response of various carcinomas. Here, we investigated characteristics of tumor-infiltrating lymphocytes (TILs), as well as T-cell evasive mechanisms in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5f1cf15715260c80acceb4198ff11e4
https://pure.eur.nl/en/publications/722825e3-6c57-4b70-bf6f-a71f203ae41a
https://pure.eur.nl/en/publications/722825e3-6c57-4b70-bf6f-a71f203ae41a